Maternal thiopurine metabolism during pregnancy in inflammatory bowel disease and clearance of thiopurine metabolites and outcomes in exposed neonates
Alimentary Pharmacology & Therapeutics2021Vol. 53(7), pp. 810–820
Citations Over TimeTop 10% of 2021 papers
Emma Flanagan, Emily K. Wright, Winita Hardikar, Miles Sparrow, William Connell, Michael A. Kamm, Peter De Cruz, Steven J. Brown, Alexander Thompson, Anthea Greenway, Ian S Westley, Murray L. Barclay, Alyson L Ross, Katerina Kiburg, Sally Bell, PICCOLO Study Group
Abstract
6-TGN levels decrease and 6-MMP levels increase in the second trimester of pregnancy. Infants are exposed to thiopurine metabolites at low levels with clearance by 6 weeks and no anaemia. The cause of infant thrombocytosis and abnormal liver biochemistry in the absence of metabolites is unclear.
Related Papers
- Importance of thiopurine S-Methyltransferase gene polymorphisms for prediction of azathioprine toxicity.(2009)
- → Azathioprine dosing and metabolite measurement in pediatric inflammatory bowel disease: does one size fit all?(2019)9 cited
- → METABOLISM OF AZATHIOPRINE(1996)4 cited
- → Role of Monitoring Thiopurine Methyltransferase (TPMT) Activity in the Individualized Therapy with Azathioprine or 6-Mercaptopurine(2008)1 cited
- Analysis of Thiopurine S-methyltransferase Genotype and Azathioprine Safety in Patients with Inflammatory Bowel Disease(2012)